Our Progress
Key Accomplishments
Since our founding in 2017, we have worked hard to advance effective treatments for pancreatitis, with the goal of developing a cure.
Developed
Best-Practices Care Protocol
for holistic pancreatitis care, vetted by top experts
companies are now working to develop therapies for pancreatitis after decades without progress
0
patients, caregivers, scientists, and advocates searching together for a cure
0
+
Developing Therapies
- Defined strategy to cure chronic pancreatitis within 10 years with input from key opinion leaders
- Identified 60 potential drug repurposing candidates that have evidence of action on pancreatitis targets
- Awarded Innovative Practices award for an international data science competition that generated 300 drug repurposing candidates
- Working with biotech Healx’s Rare Treatment Accelerator to develop a therapy for chronic pancreatitis
Improving Care
- Launched the patient-centered care strategy
- Documented and disseminated the lived experience of patients: Designing for Hope and Resilience
- Drafted specific care practices to improve patient outcomes and experience
- Established Patient-Caregiver Advisory Board
- Articulated pancreatitis-specific patient outcomes
Engaging Communities
- Reached over 77,000 patients, caregivers, clinicians, and scientists
- Increased content volume and published content in Spanish, Arabic, and Hebrew
- Held patient-focused drug development meeting with FDA & contributed to Voice of the Patient Report
- Organized & led patient panel at National Institutes of Health (NIH) meeting to expedite therapies for pancreatitis
Explore Our Progress
Roadmap to A Cure
Mission: Cure has worked tirelessly since 2017 to bring stakeholders together in search of a cure for chronic pancreatitis. View the overview of our multi-pronged strategy to cure chronic pancreatitis.
Drug Development Pipeline
When we know what biological processes are going wrong in pancreatitis (called “targets”), researchers can work to identify therapies to fix them. View our targets and the progress we’re making.
